Immunovant, Inc. · NASDAQ:IMVT

Immunovant — Corporate Update (May 2023)

7 slides from Immunovant's corporate update, May 22, 2023

  1. Slide 1: IMVT-1402 Update

    IMVT-1402 Update May 22, 2023 Exhibit 99.2

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements 2 This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "can," “may,” “might,” “will,” “would,” “should,” “

  3. Slide 3: Significant Progress in Developing IMVT-1402 as Next-Generation FcRn Inhibitor for Autoimmune Disease Therapy

    3 Significant Progress in Developing IMVT-1402 as Next-Generation FcRn Inhibitor for Autoimmune Disease Therapy Phase 1 clinical trial in healthy volunteers initiated in New Zealand Investigational New Drug (IND) application cleared by the FDA Initial data readout for single-ascending dose cohorts e

  4. Slide 4: Phase 1 Clinical Trial Objectives

    IMVT-1402 Phase 1 Clinical Trial Objectives 4 Expeditiously evaluate safety, pharmacokinetic & pharmacodynamic profile Validate the IMVT-1402 dose that achieves FcRn saturation Confirm doses for future studies 1 2 3

  5. Slide 5: Phase 1 Clinical Trial Design

    IMVT-1402 Phase 1 Clinical Trial Design* 5 Single-Ascending Intravenous Dose Single-Ascending Subcutaneous Dose Multiple-Ascending Subcutaneous Dose Fixed 300 mg Fixed 100 mg Fixed 600 mg Fixed 300 mg Fixed 600 mg Fixed 300 mg Fixed 600 mg Single Ascending Dose • 6 IMVT-1402 + 2 placebo participants

  6. Slide 6: Batoclimab Phase 1 Trial Suggests SAD Data May be Predictive of MAD Data

    6 Batoclimab Phase 1 Trial Suggests SAD Data May be Predictive of MAD Data -40 -30 -20 -10 0 10 0 10 20 30 40 50 60 Day Placebo 340 mg 680 mg -25 -20 -15 -10 -5 0 5 10 0 20 40 60 80 Day Placebo 340 mg 500 mg 765 mg Albumin % change from baseline following subcutaneous dosing of batoclimab* * Data on

  7. Slide 7: Batoclimab Phase 1 Trial Suggests SAD Data May be Predictive of MAD Data: Total IgG

    7 Batoclimab Phase 1 Trial Suggests SAD Data May be Predictive of MAD Data Total IgG % change from baseline following subcutaneous dosing of batoclimab* * Data on file Single-ascending dose Multiple-ascending dose -100 -80 -60 -40 -20 0 20 0 10 20 30 40 50 60 Day Placebo 340 mg 680 mg -60 -50 -40 -3

Immunovant — Corporate Update (May 2023) on 6ix